21 – 30 of 102
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2016
-
Mark
A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first line induction treatment of metastatic colorectal cancer: the Nordic ACT2 trial
(
- Contribution to journal › Article
- 2015
-
Mark
Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival
(
- Contribution to journal › Article
-
Mark
EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment.
(
- Contribution to journal › Article
-
Mark
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
(
- Contribution to journal › Article
- 2014
-
Mark
Cancer risk in amyloidosis patients in Sweden with novel findings on non-Hodgkin lymphoma and skin cancer
(
- Contribution to journal › Article
-
Mark
Hodgkin lymphoma after autoimmune diseases by age at diagnosis and histological subtype
(
- Contribution to journal › Article
-
Mark
Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial
(
- Contribution to journal › Article
-
Mark
Still a long way to go to achieve multidisciplinarity for the benefit of patients: commentary on the ESMO position paper (Annals Oncology Jan;25(1): 9-15, 2014).
(
- Contribution to journal › Letter
-
Mark
Autoimmune diseases associated with non-Hodgkin lymphoma: A nationwide cohort study.
(
- Contribution to journal › Article
-
Mark
One Course of Adjuvant BEP in Clinical Stage I Nonseminoma Mature and Expanded Results from the SWENOTECA group.
(
- Contribution to journal › Article